Amylyx Pharmaceuticals To Host Conference Call To Discuss The Acquisition Of Avexitide On Wednesday, July 10, 2024, at 8:00 a.m. ET; No Terms Disclosed In Press Release

7/9/24 4:33:05 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AMLX alert in real time by email

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that Amylyx' management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger BioPharmaceuticals.

Get the next $AMLX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AMLX

Date	Price Target	Rating	Analyst
11/18/2024	$3.00 → $11.00	Neutral → Outperform	Robert W. Baird
10/23/2024	$4.20 → $10.00	Neutral → Buy	BofA Securities
3/18/2024	$32.00 → $4.00	Buy → Neutral	Mizuho
3/11/2024	$27.00 → $4.00	Outperform → Market Perform	Leerink Partners
3/11/2024	$37.00 → $4.00	Outperform → Neutral	Robert W. Baird
3/8/2024		Buy → Neutral	Goldman
3/8/2024		Outperform → In-line	Evercore ISI
1/3/2024	$37.00	Outperform	Robert W. Baird

More analyst ratings

$AMLX
Financials

Live finance-specific insights

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
On track to initiate a Phase 3 program for Company's lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia (PBH) in the first quarter of 2025 Reported positive topline data from Phase 2 HELIOS clinical trial of AMX0035 in Wolfram syndrome demonstrating improvement or stabilization across all disease measures at Week 24 and sustained improvement at Weeks 36 and 48 Cash, cash equivalents and marketable securities of $234.4 million as of September 30, 2024; cash runway expected into 2026 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (N
11/7/24 7:00:00 AM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its third quarter 2024 financial results on Thursday, November 7, 2024. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (800)-836-8184 (U.S. & Canada) or +1 (646)-357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/news-ev
11/4/24 9:00:00 AM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration
- Findings from exploratory analysis of the PEGASUS trial provide preliminary evidence that AMX0035 engages multiple pathological pathways related to neurodegeneration, including tau Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the publication of exploratory analyses on cerebrospinal fluid (CSF) biomarkers from participants with Alzheimer's disease (AD) from the Phase 2 PEGASUS trial. Data analyses suggest that treatment with AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) resulted in consistent changes in AD and neurodegeneration CSF biomarkers in participants with a broad range of disease severity. The results were published in the
8/12/24 9:00:00 AM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care

$AMLX
Market Insights

Live Market Insights

Analyst Ratings For Amylyx Pharma
Analysts' ratings for Amylyx Pharma (NASDAQ:AMLX) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 2 0 0 Last 30D 0 0 1 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 1 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $6.2, a high estimate of $8.00, and a low estimate of $3.00. No alteration is observed as the current average remai
7/12/24 3:01:19 PM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for Adobe Inc. (NASDAQ:ADBE) from $700 to $635. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Adobe shares fell 1.2% to close at $557.63 on Thursday. See how other analysts view this stock. Needham slashed the price target for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) from $35 to $32. Needham analyst Serge Belanger maintained a Buy rating. KalVista Pharmaceuticals shares fell 0.6% to close at $12.50 on Thursday. See how other analysts vi
7/12/24 9:01:43 AM ET
$ADBE
$AMLX
$COST
$DAL
Computer Software: Prepackaged Software
Technology
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman Sachs Maintains Neutral on Amylyx Pharma, Raises Price Target to $4
Goldman Sachs analyst Chris Shibutani maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and raises the price target from $3 to $4.
7/12/24 6:09:10 AM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
On track to initiate a Phase 3 program for Company's lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia (PBH) in the first quarter of 2025 Reported positive topline data from Phase 2 HELIOS clinical trial of AMX0035 in Wolfram syndrome demonstrating improvement or stabilization across all disease measures at Week 24 and sustained improvement at Weeks 36 and 48 Cash, cash equivalents and marketable securities of $234.4 million as of September 30, 2024; cash runway expected into 2026 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (N
11/7/24 7:00:00 AM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its third quarter 2024 financial results on Thursday, November 7, 2024. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (800)-836-8184 (U.S. & Canada) or +1 (646)-357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/news-ev
11/4/24 9:00:00 AM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
- Improvement observed in pancreatic function, as measured by C-peptide response, following 24 weeks of treatment with AMX0035; worsening is typically expected with disease progression based on natural history studies of Wolfram syndrome - Longer-term data for all participants who have completed Week 36 and Week 48 assessments showed sustained improvement over time - Improvements or stabilization observed across all secondary endpoints, including measures of glycemic control, vision, and patient- and clinician-reported impressions of overall disease burden - AMX0035 was generally well-tolerated in all participants - Amylyx plans to meet with the FDA and other stakeholders to inform a Ph
10/17/24 9:00:00 AM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care

$AMLX
Leadership Updates

Live Leadership Updates

Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursui
4/8/24 6:24:09 PM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
- Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global products including as CMO at Ultragenyx, Alexion, and ARIAD Pharmaceuticals Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the appointment of Camille L. Bedrosian, MD, as Chief Medical Officer ("CMO"). In this role, Dr. Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations. Dr. Bedrosian brings nearly 30 years of experience addressing unmet medical needs for people with rare and serious disease
11/28/23 7:00:00 AM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
Amylyx will seek re-examination of its Conditional Marketing Authorisation Application Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the application for conditional marketing authorisation of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]), under the trade name ALBRIOZA®, for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the European Union (EU). Today's update follows the Company's May 2023 announcement that the CHMP was trending toward a negative opinion.
6/23/23 8:14:00 AM ET
$AMLX
Biotechnology: Pharmaceutical Preparations
Health Care

Amylyx Pharmaceuticals To Host Conference Call To Discuss The Acquisition Of Avexitide On Wednesday, July 10, 2024, at 8:00 a.m. ET; No Terms Disclosed In Press Release

Chat with this insight

Recent Analyst Ratings for $AMLX

$AMLX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Amylyx Pharmaceuticals upgraded by Robert W. Baird with a new price target

Amylyx Pharmaceuticals upgraded by BofA Securities with a new price target

Amylyx Pharmaceuticals downgraded by Mizuho with a new price target

$AMLX Financials

Live finance-specific insights

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

$AMLX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Co-Chief Executive Officer Klee Justin B. exercised 63,690 shares at a strike of $1.57, increasing direct ownership by 2% to 3,184,259 units (SEC Form 4)

Co-Chief Executive Officer Klee Justin B. sold $59,429 worth of shares (18,589 units at $3.20), decreasing direct ownership by 0.59% to 3,120,569 units (SEC Form 4)

Co-Chief Executive Officer Cohen Joshua B sold $59,414 worth of shares (18,589 units at $3.20), decreasing direct ownership by 0.57% to 3,220,569 units (SEC Form 4)

$AMLX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

September 2, 2022 - FDA Roundup: September 2, 2022

$AMLX Market Insights

Live Market Insights

Analyst Ratings For Amylyx Pharma

NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday

Goldman Sachs Maintains Neutral on Amylyx Pharma, Raises Price Target to $4

$AMLX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Frates James M bought $101,368 worth of shares (40,000 units at $2.53), increasing direct ownership by 21% to 233,464 units (SEC Form 4)

Director Firestone Karen bought $106,590 worth of shares (50,000 units at $2.13), increasing direct ownership by 1,000% to 55,000 units (SEC Form 4)

Director Milne George M Jr bought $219,800 worth of shares (100,000 units at $2.20), increasing direct ownership by 13% to 858,571 units (SEC Form 4)

$AMLX SEC Filings

SEC Form 10-Q filed by Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 8-K filed by Amylyx Pharmaceuticals Inc.

$AMLX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Amylyx Pharmaceuticals Inc.

SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

$AMLX Press Releases

Fastest customizable press release news feed in the world

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

$AMLX Leadership Updates

Live Leadership Updates

Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

Recent Analyst Ratings for
$AMLX

$AMLX
Analyst Ratings

$AMLX
Financials

$AMLX
Insider Trading

$AMLX
FDA approvals

$AMLX
Market Insights

$AMLX
Insider Purchases

$AMLX
SEC Filings

$AMLX
Large Ownership Changes

$AMLX
Press Releases

$AMLX
Leadership Updates